Investor Growth Capital

Kythera is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of novel prescription products for the aesthetic medicine market.  Kythera’s lead product candidate, ATX-101, is a potential first-in-class, injectable drug currently in Phase III clinical development for the reduction of submental fat.

• Sector : Healthcare
• Status : Public (NASDAQ: KYTH)
• Geographic Market : U.S.
• Investment Year : 2012
• Investment Team : Abhijeet Lele, Ashley Friedman, Yuriy Prilutskiy